Page 22 - Read Online

Chen et al. Cancer Drug Resist 2024;7:9 https://dx.doi.org/10.20517/cdr.2023.151 Page 13 of 15

DECLARATIONS
Authors’ contributions
Conceived and designed the experiments: Chen DL
Performed the experiments: Chen DL, Chen N, Sheng H
Analyzed the data: Zhang DS, Chen DL
Wrote the paper: Chen DL
All the authors read and approved the final manuscript.

Availability of data and materials
All data generated or analyzed in this study are included in this manuscript.

Financial support and sponsorship
This study was supported by the National Natural Science Foundation of China (No. 82373376) and the
Natural Science Foundation of Guangdong Province (No. 2023A1515030257).

Conflict of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Ethical approval was obtained from the ethics committee of the Sun Yat-sen University Cancer Center
(SZR2022-008), and informed consent was obtained from all the patients. Experimentation on mice was
approved by the Animal Experimentation Ethics Committee of Sun Yat-sen University Cancer Center
(L102022022003L).

Consent for publication
Not applicable.

Copyright
© The Author(s) 2024.

REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence
and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424. DOI PubMed
2. Ng O, Watts E, Bull CA, Morris R, Acheson A, Banerjea A. Colorectal cancer outcomes in patients aged over 85 years. Ann R Coll
Surg Engl 2016;98:216-21. DOI PubMed PMC
3. Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA 2021;325:669-85. DOI PubMed
4. Grassilli E, Cerrito MG. Emerging actionable targets to treat therapy-resistant colorectal cancers. Cancer Drug Resist 2022;5:36-63.
DOI PubMed PMC
5. Rainho MA, Siqueira PB, de Amorim ÍSS, Mencalha AL, Thole AA. Mitochondria in colorectal cancer stem cells - a target in drug
resistance. Cancer Drug Resist 2023;6:273-83. DOI PubMed PMC
6. Vinay DS, Ryan EP, Pawelec G, et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol
2015;35 Suppl:S185-98. DOI PubMed
7. Rizvi NA, Mazières J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients
with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol
2015;16:257-65. DOI PubMed PMC
8. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J
Med 2015;372:311-9. DOI PubMed PMC
9. Pietrantonio F, Randon G, Di Bartolomeo M, et al. Predictive role of microsatellite instability for PD-1 blockade in patients with
advanced gastric cancer: a meta-analysis of randomized clinical trials. ESMO Open 2021;6:100036. DOI PubMed PMC
10. Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric,
gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet
2021;398:27-40. DOI PubMed PMC